Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celator gets $32.5m in non-IPO stock sale

This article was originally published in Scrip

Executive Summary

Celator Pharmaceuticals raised $32.5 million from the final closing of a private placement of common stock and warrants to complete its 300-patient Phase III clinical trial for CPX-351 (cytarabine:daunorubicin) as a first-line therapy to treat secondary acute myeloid leukemia (AML) in patients between the ages of 60 and 75.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC021263

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel